References
- Bassetti M, Della Siega P, Peccori D, et al. (2015). Delafloxacin for the treatment of respiratory and skin infections. Expert Opin Investig Drugs 24:1–10
- Bauer J, Siala W, Tulkens PM, Bambeke FV. (2013). A combined pharmacodynamic, quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother 57:2726–37
- Dalvie D. (2000). Recent advances in the applications of radioisotopes in drug metabolism, toxicology and pharmacokinetics. Curr Pharm Des 6:1009–28
- Faed EM. (1984). Properties of acyl glucuronides: implications for studies of acidic drugs. Drug Metab Rev 15:1213–49
- International Conference on Harmonisation. (2009). M3(R2): Guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf [last accessed 2015]
- Nilius AM, Shen LL, Hensey-Rudloff D, et al. (2003). In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother 47:3260–9
- O’Riordan W, Mehra P, Manos P, et al. (2015). A randomised phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin–structure infections. Int J Infect Dis 30:e67–73
- Remy JM, Tow-Keogh CA, McConnell TS, et al. (2012). Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterisation. J Antimicrob Chemother 67:2814–20
- Scholar E. (2003). Fluroquinolones: past, present and future of a novel group of antibacterial agents. Am J Pharm Educ 66:164–72
- Statutory Instruments, Health and Safety, The Ionising Radiations Regulations. (1999). No. 3232, Reprinted 2000. Available from: http://www.legislation.gov.uk/uksi/1999/3232/contents/made [last accessed 2015]
- US FDA. (2008). United States Food and Drug Administration Guidance for Industry, Safety testing of drug metabolites. February 2008. Available from: http://www.fda.gov/Drugs/GuidanceCompliance